期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 135, 期 10, 页码 2352-2355出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2015.253
关键词
-
类别
资金
- NCI NIH HHS [P30 CA010815, P01 CA114046, K01 CA175269] Funding Source: Medline
NRAS-mutant melanomas are extremely aggressive and highly resistant to currently available therapeutic modalities. Hence, new targets and therapeutic strategies for NRAS-driven melanomas are needed. As blocking NRAS directly has not been possible thus far, targeting downstream NRAS effectors, such as MAPK/ERK kinase (MEK), is being evaluated as an alternative therapeutic approach. However, blocking this pathway alone has limited efficacy. In this issue, Posch et al. report on a combination approach co-targeting polo-like kinase 1 and MEK in NRAS-mutant melanomas. This combination triggers a dual blockade of the cell cycle machinery, leading to apoptosis, and providing a new strategy to treat NRAS-mutant melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据